Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK makes Brooke Shields the star of shingles vaccination push
GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and up about the power that comes from aging and how shingles threatens their health.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The results will support regulatory submissions to the FDA and EMA.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
4d
GSK CEO Is Trying to Move Past Zantac ‘Overhang’ on Shares
GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over ...
3d
GSK falls Thursday, underperforms market
GSK PLC GSK shares inched down 0.33% to £15.22 Thursday, on what proved to be an all-around favorable trading session for the ...
LancasterOnline
3d
GSK expansion project in East Donegal Township could get a tax break
East Donegal Township is considering a tax break that would benefit an expansion of the GSK vaccine packaging facility in ...
FiercePharma
3d
American Lung Association sounds alarm and launches new GSK-backed RSV campaign amid low vax rates
As the Centers for Disease Control and Prevention (CDC) finds that only one-quarter of older adults have received their ...
BioSpace
13d
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
2minutemedicine.com
13d
GSK: Depemokimab Monoclonal Antibody Reduces Asthma Attacks
Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...
6d
GSK falls Monday, underperforms market
Shares of GSK PLC GSK inched down 0.55% to £15.28 Monday, on what proved to be an all-around favorable trading session for ...
2d
OPPI appoints GSK-chief as new president
Bhushan Akshikar appointed as President of OPPI, bringing extensive experience in pharmaceutical leadership roles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
GlaxoSmithKline
RSV
European Medicines Agency
Menveo
Feedback